NCT02721732 - Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | Biotech Hunter

Enrollment

157

Participants

Timeline

Start Date

August 15, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Malignant Solid NeoplasmCarcinoma of Unknown PrimaryMetastatic Adrenal Gland PheochromocytomaMetastatic Kidney Medullary CarcinomaMetastatic Malignant Germ Cell TumorMetastatic Malignant Solid NeoplasmMetastatic ParagangliomaMetastatic Penile CarcinomaMetastatic Skin Squamous Cell CarcinomaSmall Cell CarcinomaStage III Adrenal Cortex Carcinoma AJCC v7Stage IV Adrenal Cortex Carcinoma AJCC v7Stage IV Penile Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7Unresectable Adrenal Gland PheochromocytomaUnresectable ParagangliomaUnresectable Skin Squamous Cell CarcinomaUnresectable Solid NeoplasmVascular Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER